NCT01639638View on ClinicalTrials.gov

Recurrent and Nonrecurrent Condyloma Treatment

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2014

Conditions
Recurrent CondylomaNonrecurrent Condyloma
Interventions
DRUG

PROAPOPTOTIC PEPTIDE CIGB 300

CIGB 300,in INTRALESIONAL on day 3 of each 48 HOURS.

Trial Locations (1)

C1417AZE

Laboratorio Elea SACIFyA, Capital Federal

Sponsors
All Listed Sponsors
lead

Laboratorio Elea Phoenix S.A.

INDUSTRY